Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer
Nature – The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
Related Articles
Increasing Diversity, Equity & Inclusion in the Cancer Care … : Oncology Times
An abstract is unavailable.
Improving the Transition From Inpatient to Outpatient Care in Oncology
A recent Targeted Oncology survey explores the challenges and best practices in transitioning patients with cancer from inpatient to outpatient care, featuring insights from Cristina…
Leading the Way: Approaches in Biomarker Testing for HRD, Forming the Oncology Committee – GynCancerCare OncLive
Learn the benefits of forming an oncology committee that collaborates across oncology specialties and tumor types. Explore how to create a simple and reli able…
Current Treatment Landscape – difference between unresectable (uHCC) and metastatic (mHCC)
Panelists discuss the current landscape of first-line treatment for unresectable hepatocellular carcinoma, highlighting key options and decision-making factors.
Understanding Myelodysplastic Syndromes (MDS): Diagnosis, Classification, and Risk Assessment
Panelists discuss how myelodysplastic syndromes are diagnosed, classified, and managed, covering prevalence, symptoms, risk stratification tools, prognosis for lower-risk cases, and current treatment challenges.
AI Software Learns to Identify Pancreatic Cancer Vs Cysts
A computational linguistics model designed to locate pancreatic cysts that started to locate pancreatic cancer has the potential to lead to more efficient treatment.
When Cancer and Cardiovascular Disease Intersect
The annual Global Cardio-Oncology Summit brings together health-care professionals from diverse disciplines including members of the International Cardio-Oncology Society, the only multidisciplinary p…
The dogs of Chernobyl: Demographic insights into populations inhabiting the nuclear exclusion zone
Characterization of free-breeding dogs in the Chernobyl Exclusion Zone establishes a mechanism for genetic mapping studies.
The Dogs of Chernobyl Are Experiencing Rapid Evolution, Study Suggests
Have the canines acquired strange mutations living near the power plant?
ALLO-316 Demonstrates Early Activity and Safety in Advanced CD70-Positive ccRCC
ALLO-316, a CD70-directed CAR T-cell therapy, demonstrated preliminary efficacy and safety in CD70-positive ccRCC.